Lisa M Landrum1, Elizabeth K Nugent2, Rosemary E Zuna3, Elizabeth Syzek4, Robert S Mannel2, Kathleen N Moore2, Joan L Walker2, D Scott McMeekin2. 1. Section of Gynecology Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA. Electronic address: Lisa-landrum@ouhsc.edu. 2. Section of Gynecology Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA. 3. Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA. 4. Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Abstract
OBJECTIVE: To determine the progression free survival (PFS), toxicity, and patterns of failure for early stage, high-intermediate risk (H-IR) patients in a phase II trial with adjuvant vaginal cuff brachytherapy (VCB) and three cycles of carboplatin and paclitaxel. METHODS: Surgically staged patients with stage I-IIb endometrial cancer with H-IR factors were treated with VCB (2100cGy) followed by three cycles of carboplatin (AUC 6) and paclitaxel (175 mg/m(2)). The primary endpoint was PFS at 2 years, with toxicity and sites of failure as secondary endpoints. Toxicity was assessed by patient report (CTCAE v. 3) as well as by delays or dose modifications in treatment. RESULTS: All patients completed VCB and 19/23 (83%) completed both VCB and 3 cycles of chemotherapy. Mean time to complete VCB was 14.5 days with minimal acute toxicity noted. At 6 months, all toxicity related to VCB had resolved. In total 60 cycles of chemotherapy were given, with one dose reduction (1.6%) for grade 2 neuropathy and seven delays (11.6%) in treatment due to hematologic toxicity. At a median follow-up of 44.5 months, 91% of patients remained progression free at 2 years. Four patients experienced a recurrence; they recurred both locally and distant. CONCLUSIONS: Adjuvant therapy with VCB and chemotherapy is well tolerated in a population of patients with H-IR endometrial carcinoma and provides 2 year PFS of 91%. A randomized trial is currently underway to assess whether combined VCB and chemotherapy reduces the rate of recurrence compared to external beam radiation therapy (EBRT) in this patient population.
OBJECTIVE: To determine the progression free survival (PFS), toxicity, and patterns of failure for early stage, high-intermediate risk (H-IR) patients in a phase II trial with adjuvant vaginal cuff brachytherapy (VCB) and three cycles of carboplatin and paclitaxel. METHODS: Surgically staged patients with stage I-IIb endometrial cancer with H-IR factors were treated with VCB (2100cGy) followed by three cycles of carboplatin (AUC 6) and paclitaxel (175 mg/m(2)). The primary endpoint was PFS at 2 years, with toxicity and sites of failure as secondary endpoints. Toxicity was assessed by patient report (CTCAE v. 3) as well as by delays or dose modifications in treatment. RESULTS: All patients completed VCB and 19/23 (83%) completed both VCB and 3 cycles of chemotherapy. Mean time to complete VCB was 14.5 days with minimal acute toxicity noted. At 6 months, all toxicity related to VCB had resolved. In total 60 cycles of chemotherapy were given, with one dose reduction (1.6%) for grade 2 neuropathy and seven delays (11.6%) in treatment due to hematologic toxicity. At a median follow-up of 44.5 months, 91% of patients remained progression free at 2 years. Four patients experienced a recurrence; they recurred both locally and distant. CONCLUSIONS: Adjuvant therapy with VCB and chemotherapy is well tolerated in a population of patients with H-IR endometrial carcinoma and provides 2 year PFS of 91%. A randomized trial is currently underway to assess whether combined VCB and chemotherapy reduces the rate of recurrence compared to external beam radiation therapy (EBRT) in this patient population.
Authors: Matthew M Harkenrider; Alec M Block; Kaled M Alektiar; David K Gaffney; Ellen Jones; Ann Klopp; Akila N Viswanathan; William Small Journal: Brachytherapy Date: 2016-05-31 Impact factor: 2.362
Authors: Shari Damast; Susan A Higgins; Elena Ratner; Maria C De Leon; Sheida Mani; Dan-Arin Silasi; Masoud Azodi; Alessandro Santin; Thomas Rutherford; Peter E Schwartz Journal: J Contemp Brachytherapy Date: 2015-01-26
Authors: Noemie Body; Vincent Lavoué; Olivier De Kerdaniel; Fabrice Foucher; Sébastien Henno; Aurélie Cauchois; Bruno Laviolle; Marc Leblanc; Jean Levêque Journal: BMC Cancer Date: 2016-07-19 Impact factor: 4.430
Authors: Andrea Papadia; Sara Imboden; Franziska Siegenthaler; Maria Luisa Gasparri; Stefan Mohr; Susanne Lanz; Michael D Mueller Journal: Ann Surg Oncol Date: 2016-01-20 Impact factor: 5.344
Authors: Vitaliana De Sanctis; Daniela Musio; Francesca De Felice; Francesco Marampon; Maurizio Valeriani; Paolo Bonome; Dimitri Anzellini; Giuseppe Facondo; Gianluca Vullo; Maria Massaro; Mario Di Staso; Pierluigi Bonfili; Agnieszka Chalaszczyk; Giovanni Luca Gravina; Vincenzo Tombolini; Mattia Falchetto Osti Journal: J Contemp Brachytherapy Date: 2020-04-30